Southern TOHOKU Hospital Group (STHG) has
received government grants to establish Southern TOHOKU Boron Neutron Capture
Therapy (BNCT) Research Center in partnership with the Japanese government
since 2012.

BNCT, a potentially new treatment, can
selectively target and destroy tumor cells. Southern TOHOKU BNCT differs from
conventional radiotherapies by using accelerators to generate neutrons to
irradiate boron-absorbed tumor cells.

Official clinical trials managed by a pharmaceutical company and a
medical equipment manufacturer were conducted under the supervision of the
Ministry of Health, Labour, and Welfare, Japan in 2016. The clinical
application of BNCT is expected to be a new option for cancer treatments in 2020.

Malignant
brain tumors,
head and neck cancer and various
types of cancer which are relatively near the body surface are good indications for BNCT. We are committed to bringing enlightenment while ushering in a new era of oncology science.